Problems › Business Transformation Consulting › Real Estate & Property
Most portfolio reviews in property companies fail in the diagnosis, and the diagnosis is usually commissioned from the advisers who will later propose the asset sales or refinancings. Property companies carry a specific bind here — the only asset that would sell easily is the one worth keeping, and LP consent is required above $75M. Until that is priced, net operating income will keep moving for reasons nobody can attribute, and the debate about programme spend to date will stay a matter of opinion.
Most portfolio reviews in property companies fail in the diagnosis, and the diagnosis is usually commissioned from the advisers who will later propose the asset sales or refinancings. Property companies carry a specific bind here — the only asset that would sell easily is the one worth keeping, and LP consent is required above $75M. Until that is priced, net operating income will keep moving for reasons nobody can attribute, and the debate about programme spend to date will stay a matter of opinion.
A portfolio review bundles three separable things: establishing which assets produce positive NOI after allocating debt costs, deciding which holdings to retain or divest, and securing LP consent for any move above $75M. Advisers sell them together because the diagnostic phase is priced near cost and earns its return by defining the subsequent sales or recapitalisation mandates. That is not a scandal, it is a business model, but it has a consequence worth understanding before the first engagement letter. The firm producing the review is commercially better off if the recommended changes involve large-scale asset movement.
The published failure rates for these programmes have hovered around 70% for thirty years, which is itself informative. A discipline that fails most of the time at something it has practised for decades is not failing at execution. It is usually failing earlier, at the point where a genuine question — which assets clear their cost of capital once cap-rate spread and debt maturity ladder are applied, and which of them can be changed without LP pushback — got converted into a disposal plan before it was answered.
The practical test is whether you can currently name the two or three assets whose NOI and occupancy figures are the real drag, in the order you would address them, with the cap-rate spread and remaining debt term attached. If you can, you have an execution problem, and buying execution capacity is a rational purchase. If you cannot, you have a diagnosis problem, and every pound spent on transaction support before the ranking exists is a pound spent executing the wrong disposal more thoroughly.
Corporate Strategy & Transformation (catalog id t5) is the analysis that produces the first half: what the $1.4B of assets under management actually looks like once NOI and capital costs are allocated honestly, which properties are funding which, what changes and in what order. It does not put people on the ground and does not pretend to. Where the honest answer is that you need external transaction support for nine months, it will say so — which is a cheaper way to find that out than the first mandate letter.
These three together are the signature. One on its own usually points somewhere else.
✓ The phrase 'portfolio repositioning' appears in weekly reports before any asset-by-asset NOI ranking after debt service has been produced.
✓ A scoping document for an adviser mandate exists while the debt maturity ladder and cap-rate spread by property remain uncalculated.
✓ Workstreams are titled after individual buildings or funds rather than after the specific NOI shortfalls or consent thresholds that need resolution.
The move that usually makes it worse. Commissioning the review from the firm that will later be retained to execute the sales or secure LP consent, which reliably produces a set of recommendations whose scale matches the adviser’s available mandates.
It is for you if you run or finance a property company and the word "transformation" is being used before anyone has agreed what is broken. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a property company. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Brentmoor Property Group, a sample company profile used for testing rather than a customer — $1.4B of assets under management.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Turn the $180M office maturity from threat into the seed capital and proof point for an industrial-led platform.
| Investment required | $0.9-1.1M (legal, advisory retainers, severance bridge) |
| Expected return | 11.8–14.0× on the $0.9-1.1M outlay via $9-13M self-mandate fee plus $3.4M annual G&A savings capitalized at 12× = $40.8M NPV |
| Revenue, year 1 | $9-13M advisory fee + $3.4M G&A savings run-rate |
| Revenue, year 2 | $2-4M external mandate fees from peer owners + $3.4M G&A savings |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For property companies it works through net operating income, occupancy, debt maturity ladder and cap-rate spread, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
For a mid-market company the diagnostic phase alone is commonly £75k–£250k over six to ten weeks, and the delivery phase that follows is usually several multiples of that. Large-firm day rates run roughly £1,500–£3,500 for a consultant and £4,000–£8,000 for a partner, and a typical team blends the two so the effective rate lands somewhere in the middle. The number that matters is not the day rate, though — it is the ratio of diagnosis to delivery, because that is where the scope is set.
No, and any tool that claims otherwise is selling you something. Software cannot run a programme office, hold a difficult conversation with a divisional MD, or supply forty people for nine months. What it can do is produce the analysis that decides whether you need those things, and what they should be pointed at — which is the part that is most often rushed and most expensive to get wrong.
Buy the diagnosis separately from whoever will deliver, and write the decision down before you take delivery bids. Once the two or three changes are named and the arithmetic is on paper, the delivery tender is a procurement exercise with a fixed brief. Once they are not, the tender sets its own brief, and it is always a larger one.
Materially, yes. The only asset that would sell easily is the one worth keeping, and LP consent is required above $75M — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are net operating income, occupancy, debt maturity ladder, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on net operating income and occupancy. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית